Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04803006 · ClinicalTrials.gov registry record · Phase 2
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
A Phase 2 study, sponsored by ITB-Med.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04803006: Clinical Trial Phase 2 study, sponsored by ITB-Med.
NCT04803006 is a Phase 2 study that was terminated before completion, run by ITB-Med. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04803006, a Phase 2 study, was terminated before completion, sponsored by ITB-Med.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation
Primary Outcome
The proportion of patients off immunosuppression with good safety and tolerability
Interventions
- BIOLOGICAL TCD601
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2025-10-30 |
| Phase | Phase 2 |
Why NCT04803006 stopped before completion
NCT04803006 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which TCD601 is the first listed.
NCT04803006 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04803006 about?
NCT04803006 is a clinical study titled "A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)". The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation
What is the current status of trial NCT04803006?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2023-01-17. Estimated completion is 2025-10-30.
What interventions are being tested in trial NCT04803006?
The interventions under investigation include: TCD601 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04803006?
This trial is sponsored by ITB-Med, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04803006's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI